Experimental Study of Treatment ofIntracranial G422 Glioblastoma with Bone Marrow-derived Dendritic Cells Vaccine

詹仁雅,童鹰,周永庆,杜理安,张立煌,姚杭平

DOI: https://doi.org/10.3969/j.issn.1009-153X.2003.04.003

2003-01-01

Abstract:Objectives To investigate the anti-tumor efficacy of dendritic cell (DC)-based vaccines pulsed with tumor RNA or extracts in mice with intracranial G422 glioblastoma and to discuss the feasibility of this active immunotherapy strategy for gliomas. Methods DC were isolated from mouse bone marrow precursors stimulated in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4.These DC were then pulsed with tumor RNA or extracts.The curative effect of unpulsed DC,G422 tumor RNA or extracts,or DC pulsed with G422 tumor RNA or extracts on the intracranial G422 glioblastomas were studied in the mice.CLT activity induced by DC pulsed with G422 tumor RNA or extracts was determined.The survival time of the mice was observe and analyzed.The brains were removed and examined pathologically in the mice when they died.Results Immunization using DC pulsed with tumor RNA or extracts induced G422-specific CTL responses that were significantly better than that in the mice treated with PBS,unpulsed DC,G422 tumor RNA or extracts (P0.01).The survival time of mice with intracranial glioblastomas was significandy longer in the tumor RNA or extract-pulsed DC-treated group than that in the other groups (P0.01).Conclusion DC pulsed with tumor RNA or extracts derived from autologous tumors represent a promising approach to the immunotherapy of gliomas, which can specifically activate antitumor T cells and lead to significantly prolonged survival in tumor-bearing animals.The experiment provides scientific basis for clinical use of DC vaccine.